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MeCP2Human antinuclear autoantibodies (ANAs) targeting the dense ﬁne speckled (DFS) nuclear protein DFS70,
commonly known as lens epithelium derived growth factor p75 (LEDGFp75), present a clinical puzzle since
their signiﬁcance remains elusive. While their frequencies are low in ANA-positive autoimmune rheumatic
diseases, they are relatively elevated in clinical laboratory referrals, diverse inﬂammatory conditions, and
‘apparently’ healthy individuals. We reported previously that DFS70/LEDGFp75 is an autoantigen in prostate
cancer that closely interacts with another 70 kD DFS nuclear protein, methyl CpG binding protein 2 (MeCP2).
This led us to investigate if anti-DFS sera exclusively target DFS70/LEDGFp75 or also recognize MeCP2. Using
several complementary autoantibody detection platforms and cellular/molecular approaches we evaluated 65
human sera producing anti-DFS autoantibodies. Our results show that these antibodies are highly speciﬁc for
DFS70/LEDGFp75 and do not target MeCP2. Establishing the speciﬁcity of anti-DFS autoantibodies has
implications for increasing our understanding of their biological signiﬁcance and clinical utility.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Circulating antinuclear autoantibodies (ANAs) are an immunological
hallmark of systemic autoimmune rheumatic diseases, but can also be
found in patients with cancer and other inﬂammatory and autoimmune
conditions [1,2]. These autoantibodies are typically detected by indirect
immunoﬂuorescence (IIF)microscopy using the HEp-2-ANA test, which
remains the recommended method for ANA screening [3]. Their diag-
nostic and prognostic value, as well as their utility as probes in molecu-
lar cell biology, have been widely investigated [1].
The nuclear dense ﬁne speckled (DFS) pattern is one of the
most commonly observed IIF-ANA patterns in patients who are ANA-
positive, have no evident diagnosis of ANA-associated rheumatic auto-
immune diseases (AARD), and have been referred to clinical laborato-
ries for ANA testing because of non-speciﬁc complaints and symptoms
[4–6]. This pattern is produced by autoantibodies recognizing uniformlyities and Molecular Medicine,
rsity School of Medicine, Loma
. This is an open access article underdistributed DFS located throughout interphase nuclei, often excluding
the nucleoli, and in condensed mitotic chromosomes [6,7]. These anti-
DFS autoantibodies are typically of the IgG class (although IgE antibod-
ies have been also detected), and react by immunoblottingwith a nucle-
ar protein of approximately 70 kD protein designated DFS70 [4,7,8],
most commonly known as lens epithelium-derived growth factor p75
(LEDGF/p75) [9]. Anti-DFS70/LEDGFp75 autoantibodies have been
found at varied frequencies (typically ranging from 6% to 20%), and
often at high titers (≥1:640), in diverse inﬂammatory and atopic condi-
tions, prostate cancer, certain non-AARD autoimmune conditions, eye
diseases, as well as in apparently healthy individuals [9–12].
In addition to its possible role in autoimmunity, DFS70/LEDGFp75
has emerged in recent years as a key protein that facilitates the integra-
tion of human immunodeﬁciency virus 1 (HIV-1) into host chromatin
by interactingwith theHIV-integrase and tethering it to transcriptional-
ly active sites [13,14]. This autoantigen has also surfaced as a key stress
oncoprotein upregulated in prostate cancer and other cancer types that
promotes cell proliferation, resistance to cell death and chemotherapy,
DNA repair, clonogenicity, angiogenesis, and tumor growth [15–24].
DFS70/LEDGFp75 normally functions as a transcription coactivator
that is upregulated and activated as part of the cellular response to
environmental stressors such as oxidative stress, heat, UV radiation,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with speciﬁc transcription factors and chromatin associated proteins at
transcriptionally active sites to regulate the expression of speciﬁc stress,
inﬂammatory, antioxidant, and cancer-associated genes [27–33]. Its cel-
lular interacting partners include pogo transposable element PogZ, c-
Myc interacting protein JPO2, Cdc7-activator of S-phase kinase (ASK),
leukemia-associated transcription complex Menin-MLL (mixed lineage
leukemia), and the methyl CpG binding protein MeCP2 [34–38]. These
interacting partners co-localize with DFS70/LEDGFp75 in the nucleus,
displaying the characteristic DFS-IIF pattern.
The target antigen speciﬁcity of serum autoantibodies producing the
typical DFS-IIF pattern remains to be ﬁrmly established. An emerging
question is whether all patient sera that are positive for the DFS-IIF pat-
tern speciﬁcally target DFS70/LEDGFp75, or also contain antibodies
against interacting partners of this autoantigen, or other related pro-
teins, that share the same nuclear localization pattern. For instance,
Bizzaro and colleagues [39] reported that over 20% of human sera show-
ing the DFS-IIF pattern in HEp-2 substrates also reacted strongly against
reticular ﬁbers of the lens and the corneal epithelium. Immunohisto-
chemical analysis of these putative anti-DFS70/LEDGFp75 positive sera
in mouse lens tissues revealed different distribution patterns, suggest-
ing that companion autoantibodies targeting other autoantigens may
also be present in these sera [39]. These authors suggested that the
characteristic DFS-IIF pattern produced by anti-DFS70/LEDGFp75 auto-
antibodies in HEp-2 cells might also be produced by companion anti-
bodies targeting interacting partners of this autoantigen. They also
pointed that it is not easy to recognize the DFS pattern solely by IIF mi-
croscopy in HEp-2 cells and that alternative platforms are necessary to
accurately detect the anti-DFS70/LEDGFp75 antibodies [40], a conclu-
sion that has been supported recently by other groups [41,42]. Address-
ing the target antigen speciﬁcity of the DFS-IIF autoantibody pattern is
therefore important to advance our understanding of its clinical utility
and biological signiﬁcance.
MeCP2 is a cellular interacting partner of DFS70/LEDGFp75 that is
mutated in Rett syndrome and functions as a chromatin remodeling
protein that contributes to gene activation or repression depending on
the cellular andmolecular context [43]. Our group demonstrated previ-
ously that MeCP2 interacts with DFS70/LEDGFp75 in cancer cells to reg-
ulate the promoter activity of heat shock protein 27 (HSP27) gene [38].
MeCP2 displayed a nuclear DFS-IIF pattern strikingly similar to that of
DFS70/LEDGFp75, and the two proteins co-localized in the nucleus
when targeted endogenously by speciﬁc antibodies andwhen ectopical-
ly overexpressed in cells [38]. Furthermore, both proteins are recog-
nized by antibodies in immunoblots around the 70–75 kD region.
These observations raised the possibility that MeCP2 could also be a
target of the anti-DFS sera. In this study, we determined if human sera
presenting the DFS-IIF pattern speciﬁcally react with either DFS70/
LEDGFp75 or MeCP2, or target both proteins.2. Materials and methods
2.1. Cell lines and antibodies
PC3 and DU145 prostate cancer cell lines and U2OS osteoblastoma
cells were acquired from the American Type Culture Collection (ATCC).
Cell lines were cultured in RPMI 1640 medium supplemented with 10%
fetal bovine serum (Corning), penicillin-streptomycin (Corning), and
gentamycin (Gibco, Life Technologies) as recommended by the supplier
in a humidiﬁed incubator with 5% CO2 at 37 °C. The following antibodies
were used in this study: mouse monoclonals anti-MeCP2 (Abcam) and
anti-β-actin (Sigma-Aldrich); rabbit polyclonals anti-DFS70/LEDGFp75
(Bethyl Laboratories Inc.) and anti-MeCP2 (Proteintech group); and
ﬂuorescein isothiocyanate (FITC)-conjugated goat anti-human IgG
(Invitrogen), and FITC- and rhodamine-conjugated goat anti-rabbit IgG
(Invitrogen) secondary antibodies.2.2. Human sera and ANA testing
Seventy-one human serum samples with no patient identiﬁers were
obtained from serum banks in Sao Paulo, Brazil (Dr. Luis E. Andrade),
Luxembourg (a kind gift from Professor Rene-Louis Humbel), and La
Jolla, California, USA (a kind gift from Dr. Eng M. Tan). These sera had
been previously determined by the donor laboratories to have a
suspected DFS-IIF pattern in HEp-2-ANA substrates, and were obtained
from patients with diverse disease conditions [4,7]. They were exam-
ined under the approval of the Institutional Review Board of Loma
Linda University. Sera were re-evaluated in our laboratory for the pres-
ence of ANAs using the NOVA Lite HEp-2-ANA kit/substrate slides
(Inova Diagnostics, San Diego, CA) according to the manufacturer's in-
structions. Brieﬂy, human sera and commercial anti-DFS70/LEDGFp75
or MeCP2 antibodies were added to individual wells of HEp-2-ANA
slides. Serum and antibodieswere diluted at 1:80 or 1:160 in PBS for ini-
tial ANA screening and further diluted in subsequent tests according to
the strength of their reactivity. FITC- or rhodamine-conjugated second-
ary antibodies were used at 1:100 dilution for the detection of primary
antibodies. Visualization of ANA patterns and image acquisition were
done on a Keyence BZ9000 Biorevo ﬂuorescence microscope.
2.3. Confocal microscopy
Endogenous DFS70/LEDGFp75 and MeCP2 were visualized in PC3
and U2OS cells using speciﬁc antibodies as described previously [38].
Brieﬂy, cells were ﬁxed with 4% formaldehyde and permeabilized with
0.5% Triton X-100. Following ﬁxation/permeabilization, cells were co-
incubated with validated human anti-DFS70/LEDGFp75 sera and a
rabbit anti-MeCP2 antibody, both used at 1:200 dilution, at room tem-
perature for 30min. After incubationwith corresponding secondary an-
tibodies labeled with either FITC or rhodamine, cells were mounted
with mounting medium (Vectashield, Vector Labs) containing 4′,6-
diamidino-2-phenylindole (DAPI). Antibody reactivity was visualized
by confocal microscopy using a Zeiss LSM 710 NLO microscope with
63× oil immersion objective and appropriate ﬁlters. Image analysis
and acquisition were done using ImageJ software.
2.4. Immunoblotting analysis
Immunoblotting procedures were essentially conducted as previ-
ously described [38]. Concisely, SDS-PAGE (NuPAGE 4–12% gels, Life
Technologies) was used to separate total cellular proteins followed by
transfer to nitrocellulose membranes (GE Healthcare Life Sciences).
Membranes were cut into strips and blocked overnight with 5% dry
milk solution in TBS-T buffer (20 mM Tris–HCl, pH 7.6, 140 mM NaCl,
0.15% Tween 20) and individual strips were then probed with different
patient sera or commercial antibodies for 2 h. After several washes with
TBS-T, the individualmembrane stripswere incubatedwith appropriate
horseradish peroxidase (HRP)-conjugated secondary antibodies. Detec-
tion of antibodies bound to proteins was achieved by enhanced chemi-
luminescence (Thermo Fisher Scientiﬁc Pierce).
2.5. QUANTA-Flash DFS70 chemiluminescent immunoassay
Sera that exhibited the DFS-IIF pattern and recognized a 75 kD pro-
tein band by immunoblotting were further analyzed by the QUANTA
Flash® CIA to conﬁrm the presence of anti-DFS70/LEDGFp75 antibodies
as described previously [11]. This assay is hereafter referred to as
DFS70-CIA and uses recombinant DFS70/LEDGFp75 antigen coated
onto paramagnetic beads. Brieﬂy, the relative light units (RLUs) were
proportional to the amount of isoluminol conjugate bound to the anti-
human IgG, which in turn was proportional to the amount of serum au-
toantibodies bound to recombinant DFS70/LEDGFp75 antigen on the
beads. Using a standard curve, RLU values were converted into calculat-
ed units (CU). Sera with CUs less than 20 were considered negative for
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and N300 were considered low positive, moderately positive, and high
positive, respectively.
2.6. Generation of PC3 cells with stable overexpression and depletion of
DFS70/LEDGFp75
PC3 cells stably overexpressingDFS70/LEDGFp75were generated by
transduction using retroviral vectors encoding the full-length protein
(pLNC_LEDGF BC-Ires-bsd) as described previously [44]. PC3 cells with
stable depletion of DFS70/LEDGFp75 were generated using a miRNA-
based short hairpin interfering RNA (shRNA) cloned into pLNC_MCS
plasmid (pLNC-2x miRNA_L3 ZeoR) as described previously [44]. A
shSCR (scrambled) sequence served as the non-interfering shRNA con-
trol. Transduced cells were selected with zeocin (200 μg/ml). DFS70/
LEDGFp75 overexpression or depletion was assessed by RT-PCR and
immunoblotting.
2.7. Immunoadsorption of anti-DFS70/LEDGFp75 antibodies with
recombinant antigen
Anti-DFS70/LEDGFp75 autoantibody reactivity in HEp-2 substrates
was diminished by immunoadsorption with a recombinant DFS70/
LEDGFp75 peptide (component of HEp-2 Select, Inova Diagnostics) as
described previously [6]. Brieﬂy, the DNA sequence encoding a DFS70/
LEDGFp75 peptide corresponding to the autoepitope (amino acids
349–435) was cloned into pIExBac-3 expression vector and expressed
in insect Sf9 cells or Escherichia coli. The puriﬁed recombinant DFS70/
LEDGFp75 peptide was diluted in TBS-T at ﬁnal concentration of ap-
proximately 0.4 mg/ml and the resulting solution was then used asFig. 1.Detection of anti-DFS70/LEDGFp75 autoantibodies in human sera. A) Representative hum
inHEp-2-ANA slides. Yellow arrows point to the staining ofmitotic chromosomes. Correspondin
plot of serawith suspected anti-DFS autoantibodies thatwere tested using theDFS70-QuantaFla
D) Blots showing immunoreactivity of selected anti-DFS sera against a 75 kD protein in wholesample diluent to adsorb the anti-DFS sera. Sera diluted at 1:80 in
TBS-T with and without the peptide were then evaluated by the HEp-
2-ANA test and by immunoblotting.
3. Results
3.1. Detection of anti-DFS70/LEDGFp75 autoantibodies in human
anti-DFS sera
Seventy-one human sera suspected of containing anti-DFS autoanti-
bodies were re-examined by IIF microscopy in HEp-2-ANA test slides.
Sixty-ﬁve of these sera recognized the characteristic DFS-IIF pattern, de-
ﬁned by interphasic nuclear DFS and strong staining of condensed
mitotic chromosomes (Fig. 1A), whereas 6 recognized other ANA pat-
terns. The DFS-IIF pattern was observed at various titers and was the
only ANA pattern observed in all but one of the 65 sera. This particular
serum contained both anti-DFS and anti-p80 coilin antibodies, which
have been found to co-exist in some patients [45]. Sixty-four of the
DFS-IIF positive sera were available for further analysis by DFS70-CIA,
of which 61 (95.3%) tested positive for the presence of anti-DFS70/
LEDGFp75 autoantibodies and 3 (4.7%) tested negative (Fig. 1B, C).
The 6 seramentioned above that recognized other IIF patterns also test-
ed negative for DFS70-CIA. Twenty-four (37.5%) of the 61 sera were
considered to be low positive, 21 (32.8%) moderately positive, and 16
(25%) high positive by DFS70-CIA based on CU values (Fig. 1C).
Next we evaluated the reactivity of the sera by immunoblotting
using whole lysates from PC3 prostate cancer cells. We chose this cell
line because in previous studies our group demonstrated that DFS70/
LEDGFp75 is overexpressed in prostate cancer cells and tumor tissues,
and is the target of autoantibodies in certain patients with prostatean anti-DFS serumdisplaying the characteristic dense ﬁne speckled nuclear pattern (FITC)
gDAPI staining is shown in black andwhite for better visualization of chromatin. B) Scatter
sh chemiluminescent immunoassay (DFS70-CIA). C) Pie chart of data from the scatter plot.
PC3 cell lysates.
Table 1
Detection of anti-DFS70/LEDGFp75 autoantibodies by immunoblotting and DFS70-CIA in
sera.
Serum Immunoblotting DFS70-CIA
DFS 1 Strong High positive
DFS 2 Strong Positive
DFS 3 Strong Positive
DFS 4 Strong High positive
DFS 5 Strong Positive
DFS 6 Strong High positive
DFS 7 Strong Positive
DFS 8 Strong High positive
DFS 9 Strong High positive
DFS 10 Strong High positive
DFS 11 Moderate Low positive
DFS 12 Strong Positive
DFS 13 Moderate Low positive
DFS 14 Strong Positive
DFS 15 Weak Low positive
DFS 16 Strong Positive
DFS 17 Strong Low positive
DFS 18 Strong Positive
DFS 19 Strong High positive
DFS 20 Moderate Positive
DFS 21 Strong High positive
DFS 22 Moderate Positive
DFS 23 Weak Low positive
DFS 24 Weak Low positive
DFS 25 Moderate Positive
DFS 26 Moderate High positive
DFS 27 Moderate Positive
DFS 28 Moderate Positive
DFS 29 Moderate High positive
DFS 30 Moderate High positive
DFS 31 Weak Low positive
DFS 32 Moderate Positive
DFS 33 Weak Low positive
DFS 34 Moderate Positive
DFS 35 Moderate Positive
DFS 36 Weak Low positive
DFS 37 Weak Low positive
DFS 38 Moderate High positive
DFS 39 Moderate Positive
DFS 40 Weak Low positive
DFS 41 Very weak Negative
DFS 42 Moderate Positive
DFS 43 Weak Low positive
DFS 44 Weak Low positive
DFS 45 Moderate High positive
DFS 46 Weak Low positive
DFS 47 Weak Low positive
DFS 48 Weak High positive
DFS 49 Weak Low positive
DFS 50 Weak Low positive
DFS 51 Weak Low positive
DFS 52 Very weak Negative
DFS 53 Moderate Positive
DFS 54 Weak Low positive
DFS 55 Weak Low positive
DFS 56 Very weak Negative
DFS 57 Weak Low positive
DFS 58 Moderate High positive
DFS 59 Weak Low positive
DFS 60 Strong High positive
DFS 61 Weak Low positive
DFS 62 Moderate Positive
DFS 63 Weak Low positive
DFS 64 Moderate Positive
CIA, chemiluminescence immunoassay; DFS, denseﬁne speckles; DFS70, denseﬁne speck-
led protein of 70 kD; LEDGF/p75, lens epithelium derived growth factor protein of 75 kD.
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cell lines [38]. Immunoblotting analysis revealed that the 61 sera that
tested positive byDFS70-CIA also tested positive, albeit at varying inten-
sities, for the presence of anti-DFS70/LEDGFp75 autoantibodies
(Table 1; also see representative serum immunoreactivities in Fig. 1D).
The 3 sera that tested negative by DFS70-CIA showed very weak ornegative reactivity against a 75 kD band by immunoblotting (Table 1).
Table 1 shows a strong concordance between anti-DFS70/LEDGFp75 an-
tibody speciﬁcity by HEp-2-ANA test, DFS70-CIA, and immunoblotting.
Thus, using different antibody detection platformswewere able to con-
ﬁrm the presence of these autoantibodies in most human sera with
suspected DFS-IIF pattern (64 of 71) that were available to us at the
time we initiated this study.
3.2. Similarities in the reactivity of antibodies recognizing DFS70/LEDGFp75
and MeCP2
To determine if the DFS-IIF positive sera also contained antibodies to
MeCP2, an interacting partner of DFS70/LEDGFp75 in prostate cancer
cells that also migrates around the 70–75 kD region [38], we compared
the reactivity of human and commercial antibodies to these two pro-
teins by IIF microscopy and immunoblotting. As expected, the classical
DFS-IIF pattern displayed by the anti-DFS70/LEDGFp75 human sera
was also reproduced in HEp-2 cells using a commercial rabbit anti-
DFS70/LEDGFp75 antibody (Fig. 2A). Interestingly, a rabbit antibody
recognizing MeCP2 also showed a very similar DFS-IIF reactivity in
HEp-2 cells. Immunoblotting analysis using PC3 and DU145 prostate
cancer cell lysates, revealed that two commercial anti-MeCP2 antibod-
ies also recognized a doublet protein around the 75 kD region, similar
to the reactivity of the anti-DFS70/LEDGFp75 human and rabbit anti-
bodies (Fig. 2B). One of the anti-MeCP2 antibodies also reacted weakly
with a 55 kD band.
To further explore the similarities in IIF reactivity between antibod-
ies to DFS70/LEDGFp75 and MeCP2, we co-incubated a prototype
human anti-DFS70/LEDGFp75 serum (positive by HEp-2-ANA test,
DFS70-CIA, and immunoblotting) with the rabbit anti-MeCP2 antibody
in HEp-2 ANA slides. We observed that the two antibodies produced
a strikingly similar DFS-IIF pattern with their target antigens co-
localizing in HEp-2 cells (Fig. 3A). We conﬁrmed this co-localization
using several prototype anti-DFS human sera (data not shown). Control
experiments with single antibody incubation revealed that each anti-
body produced the DFS-IIF pattern independently, without cross-
reactivity or bleed-through when the FITC or rhodamine signals were
imaged separately (Fig. 3B, C). Confocal microscopy analysis of PC3
and U2OS cells co-incubated with the two antibodies (human anti-
DFS serum and rabbit anti-MeCP2) also showed strong co-localization
in nuclear DFS andmetaphase chromosomes (Fig. 3D, E). This is consis-
tent with our previous observation that DFS70/LEDGFp75 and MeCP2
co-localize in cancer cells and together regulate HSP27 promoter
activity [38].
3.3. Immunoblotting analysis of anti-DFS serum reactivity against proteins
from cells with stable overexpression or depletion of DFS70/LEDGF/p75
In order to determine if human sera that were immunoreactivewith
DFS70/LEDGFp75 also contained antibodies to MeCP2, we selected a
sub-group of 18 representative sera that produced the DFS-IIF pattern
in HEp-2-ANA test slides, reacted with a 75 kD protein band by immu-
noblotting (Fig. 1D), and tested positive by DFS70-CIA. To conﬁrm the
speciﬁcity of these sera for anti-DFS70/LEDGFp75 autoantibodies, we
ﬁrst tested them by immunoblotting against lysates from PC3 cells
with stable overexpression or depletion of DFS70/LEDGF/p75 protein.
We hypothesized that if the sera reacted speciﬁcally with DFS70/
LEDGFp75, we would then observe increased reactivity against the
75 kD protein band in lysates from cells overexpressing this protein,
concomitant with decreased or no reactivity in lysates from cells with
DFS70/LEDGFp75 depletion. However, if the human sera also contained
autoantibodies to MeCP2, we would then be able to observe reactivity
against a 75 kD protein in PC3 lysates with DFS70/LEDGFp75 depletion.
All the selected sera displayed elevated reactivity against the 75 kD
protein band in PC3 cells overexpressing DFS70/LEDGFp75 (OE)
compared to PC3 cells transfected with empty control vector (Vec)
Fig. 2.Antibodies toDFS70/LEDGFp75 andMeCP2display similar features in their reactivity. A)DFS-IIF pattern (FITC) in HEp-2-ANA slides produced by human anti-DFS sera (a representative
serum is shown), rabbit antibody to DFS70/LEDGFp75, and rabbit antibody to MeCP2. Corresponding DAPI images are shown in black and white for better visualization of chromatin.
B) Immunoblots showing the reactivity of human anti-DFS sera (two representative sera are shown), rabbit antibody to DFS70/LEDGFp75, rabbit antibody toMeCP2, andmouse monoclonal
antibody to MeCP2, against whole protein lysates from PC3 and DU145 cells. Beta-actin was used as loading control.
245A. Basu et al. / Clinical Immunology 161 (2015) 241–250(representative sera shown in Fig. 4). This was consistent with the ob-
servation that these sera had tested positive for autoantibodies to this
protein using the different detection platforms described above. By con-
trast, the two commercial antibodies against MeCP2 reacted with simi-
lar intensity with the 75 kD protein band in both PC3-Vec and PC3-OE
lysates, consistent with their speciﬁcity for MeCP2 (Fig. 4).
We then probed the sera against lysates from PC3 cells with stable
depletion of DFS70/LEDGFp75 (shRNA) and scrambled control shRNA
(SCR). We observed that all the selected human anti-DFS sera reacted
speciﬁcally with DFS70/LEDGFp75. This was evident from the absence
of, or limited, reactivity of the sera with the 75 kD protein band in the
PC3-shRNA cells (representative sera shown in Fig. 5). By contrast, de-
pletion of DFS70/LEDGFp75 did not affect the reactivity of the commer-
cial anti-MeCP2 antibodies against the 75 kD protein in PC3-SCR or PC3-
shRNA lysates. These results suggest that the selected group of human
sera, which were conﬁrmed to contain anti-DFS70/LEDGFp75 autoanti-
bodies using different detection platforms, do not react against MeCP2.
3.4. Conﬁrmation of anti-DFS70/LEDGFp75 antibody speciﬁcity in anti-DFS
sera by preadsorption with autoepitope peptide
To further conﬁrm that human sera producing the classical DFS-IIF
pattern preferentially react with DFS70/LEDGFp75 and not with
MeCP2, we preadsorbed the selected 18 anti-DFS human sera with a re-
combinant DFS70/LEDGFp75 antigen corresponding to the autoepitope(amino acids 349–435) recognized by anti-DFS autoantibodies [47]. We
hypothesized that if the pre-adsorption abolished the reactivity of the
18 sera against DFS70/LEDGFp75 by immunoblotting and HEp-2-IIF
analyses, then the sera would be speciﬁc for this protein and would
not contain antibodies to MeCP2. We observed that the recombinant
autoepitope peptide abolished the reactivity of all the 18 anti-DFS
sera, strongly suggesting their speciﬁcity for DFS70/LEDGFp75 (repre-
sentative sera shown in Fig. 6A). As expected, the autoepitope peptide
did not preadsorb the reactivity of the commercial anti-MeCP2 antibod-
ies, as shown by immunoblotting (Fig. 6A). It should be noted that the
autoepitope peptide did not preadsorb the reactivity of the commercial
rabbit antibody to DFS70/LEDGFp75, which was raised against a C-
terminal region of this autoantigen that fell outside the autoepitope
(amino acids 480–530). IIF analysis revealed that preadsorption of
human anti-DFS sera with the autoepitope peptide abrogated their nu-
clear reactivity in HEp-2 cells but did not affect the nuclear reactivity of
rabbit anti-MeCP2 antibodies (Fig. 6B). These results further conﬁrmed
the speciﬁcity of these sera for DFS70/LEDGFp75.
4. Discussion
During the past decade several groups have documented the pres-
ence of high titer, anti-DFS70/LEDGFp75 IgG in apparently healthy indi-
viduals and in a wide variety of non-AARD inﬂammatory conditions,
including interstitial cystitis, atopic dermatitis, alopecia areata, cataracts
Fig. 3.Nuclear colocalization of DFS70/LEDGFp75 andMeCP2. A) A representative human anti-DFS serum displays the characteristic DFS-IIF pattern in HEp-2-ANA slides, detected with a
FITC-labeled secondary anti-human antibody (green). This pattern was also produced by a rabbit anti-MeCP2 antibody co-incubated with human anti-DFS serum in the same cells, and
detected with rhodamine-labeled secondary anti-rabbit antibody (red). Merged images show the yellow-orange staining typical of colocalization. B) Staining of HEp-2 cells with only
human anti-DFS serum. C) Staining of HEp-2 cells with only rabbit anti-MeCP2 antibody. D) Colocalization of DFS70/LEDGFp75 and MeCP2 in PC3 cells (D) and U2OS cells (E), each
simultaneously incubated with human anti-DFS serum (green) and anti-rabbit MeCP2 antibody (red). Merged images show the yellow-orange staining typical of colocalization.
Corresponding DAPI images are shown in black and white for better visualization of chromatin.
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tate cancer [4–12,46]. There is growing consensus that these auto-
antibodies are present at low prevalence in patients with AARD,
and when found in these patients are usually accompanied by other
AARD-marker autoantibodies such as anti-DNA and anti-Sm [4–12,41,
48,49]. This has led to the hypothesis that when they are the sole ANA
speciﬁcity in the patient's serum, these autoantibodies could be used
as exclusion biomarkers of AARD diagnosis in ANA-positive individuals
[5,6,11]. This was illustrated in a recent case report of a childwith respi-
ratory distress who presented high-titer anti-DFS70/LEDGFp75 autoan-
tibodies as the sole ANA speciﬁcity and with no clinical evidence of
SARD [50]. In that particular case, these antibodies were used to rule
out suspected autoimmune disease, guiding the clinicians to the proper
therapeutic intervention [50].
A challenge facing clinicians that refer patients with non-speciﬁc
complaints to clinical diagnostic laboratories for ANA screening is how
to interpret adequately a positive anti-DFS antibody result. Such result,
if interpreted out of the context of our current knowledge of this
autoantigen-autoantibody system,might cause undue concern and anx-
iety among patients and their families, and even lead to unnecessary
therapeutic interventions [41]. Likewise, a challenge facing routine di-
agnostic laboratories is how to accurately identify the characteristic
DFS-IIF pattern and the presence of anti-DFS70/LEDGFp75 autoanti-
bodies in patient serum, given the similarity of this pattern, particularlyin interphasic nuclei, to other ﬁne speckled ANA patterns [40–42]. For
instance, clinical laboratory personnel who are not familiar with the
DFS-IIF pattern may confuse it, especially when present at low titers,
with the homogeneous or the ‘quasi-homogeneous’ ANA patterns or
with other nuclear DFS-IIF patterns lacking mitotic chromatin staining,
leading to false positive tests for the presence of AARD-associated
ANAs, with their unintended consequences [41].
In this studywe used a combination of complementary antibody de-
tection platforms and molecular/cellular approaches to accurately and
unambiguously establish the monospeciﬁcity of anti-DFS70/LEDGFp75
autoantibodies in sera that produce the characteristic DFS-IIF pattern
in HEp-2-ANA substrates. The high concordance of our results in the
three detection platforms (HEp-2-ANA test, DFS70-CIA, and immuno-
blotting) reinforced the notion that accurate detection of anti-DFS70/
LEDGFp75 autoantibodiesmay require, in addition toHEp-2-ANA, a sec-
ond conﬁrmatory detectionmethod. The use of cell lysates with DFS70/
LEDGFp75 depletion and a recombinant peptide encompassing the
autoepitope region for anti-DFS autoantibody immunoadsorption
were critical to validate our results. These results clearly conﬁrmed
that the major autoepitope is recognized by the majority, if not by all
the anti-DFS70/LEDGFp75 positive patients and that the CIA reliably de-
tects the antibodies. Our results also support the argument that inter-
laboratory discrepancies regarding detection of anti-DFS70/LEDGFp75
autoantibodies during routine HEp-2-ANA screening could be rendered
Fig. 4. Immunoreactivity of human anti-DFS sera against cells with and without DFS70/LEDGFp75 overexpression. Immunoblots showing the reactivity of representative human anti-DFS
sera against DFS70/LEDGFp75 in whole lysates from PC3 cells stably overexpressing this protein (OE) and stably transfected with control empty vector (Vec). Note increased intensity of
the 75 kD protein band in cells overexpressing DFS70/LEDGFp75. Beta-actin was used as loading control.
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the ANA results [42]. It should be emphasized, however, that immuno-
blotting procedures for anti-DFS autoantibody detection might not be
the best practice for routine diagnostics given their complexity and
labor intense nature. A single, simple, and well-characterized assay
that has been widely validated in various international laboratories
would be ideal for this purpose.
Another important issue that should be considered in the identiﬁca-
tion of theDFS-IIF pattern in routine clinical laboratory ANA screening isFig. 5. Immunoreactivity of human anti-DFS sera against cells with and without DFS70/LEDGFp
against DFS70/LEDGFp75 in whole lysates from PC3 cells with stable shRNA-mediated deplet
disappearance of the 75 kD protein band in cells with DFS70/LEDGFp75 depletion (shRNA). Bethe possibility that autoantibodies to nuclear autoantigens other than
DFS70/LEDGFp75 may also produce this pattern. We explored this pos-
sibility by focusing on MeCP2, a close interacting partner of DFS70/
LEDGFp75 with similar nuclear localization and molecular weight [38].
As mentioned earlier, DFS70/LEDGFp75 is a component of chromatin-
associated protein complexes that participate in the regulation of gene
expression, and some of its interacting partners, including MeCP2, co-
localize with this protein, producing an identical DFS-IIF pattern
[34–38]. Our combined results demonstrated that human sera75 depletion. Immunoblots showing the reactivity of representative human anti-DFS sera
ion of this protein and stably transfected with scrambled shRNA control (SCR). Note the
ta-actin was used as loading control.
Fig. 6. Immunoadsorption of anti-DFS sera with autoepitope-containing peptide. A) Immunoblots showing the abolition of anti-DFS/LEDGFp75 reactivity against PC3 lysates in human
anti-DFS sera preadsorbed with a peptide corresponding to the C-terminal autoepitope region of DFS70/LEDGFp75 (representative sera shown). Preadsorption of anti-MeCP2 antibodies
with the autoepitope-containing peptide did not abrogate their immunoreactivity. Similarly, preadsorption of the rabbit anti-DFS70/LEDGFp75 antibody, which targets a region outside
the autoepitope, did not abrogate its immunoreactivity. Beta-actinwas used as loading control. B) Preadsorption of representative human anti-DFS serumwith the autoepitope-containing
peptide abolished its immunoreactivity (green) in HEp-2-ANA slides. However, preadsorption of rabbit anti-MeCP2 antibody did not abolish its immunoreactivity (red) in HEp-2-ANA
slides. Corresponding DAPI images are shown in black and white for better visualization of chromatin.
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LEDGFp75 and not MeCP2. We cannot rule out the possibility that
MeCP2 could be the target of human autoantibodies in speciﬁc disease
contexts given that we did not examine hundreds of anti-DFS sera for
the presence of these autoantibodies. However, the fact that none of
the 18 sera selected for their moderate to strong anti-DFS immunoreac-
tivity by HEp-2-ANA, DFS70-CIA, and immunoblotting showed reactivi-
ty against MeCP2, or any other common antigen band in immunoblots,
provides compelling evidence that when present as the sole ANA pat-
tern in serum, the DFS-IIF pattern is monospeciﬁc for DFS70/LEDGFp75.
This suggests that this autoantigen by itself, and not a protein complex
in which it may be involved, is the immunogen inciting this antibody
response in susceptible individuals.
While we do not know what makes DFS70/LEDGF/p75 immuno-
genic, it is interesting to note that the autoepitope region recognized
by its cognate autoantibodies (residues 349–435) lies within a highly
conserved, functional domain called the integrase binding domain
(IBD) [51]. This domain is recognized by the HIV-1 integrase (residues
347–429) to facilitate viral integration into the host genome, and isvery important for DFS70/LEDGFp75 stress survival activities and inter-
actions with chromatin-associated proteins, with the exception of
MeCp2, which binds to its N-terminal region [34,38,51–53]. The auto-
immune targeting of the IBD of DFS70/LEDGFp75 is consistent with
the notion that autoepitope regions are locatedwithin highly conserved
and functional domains of nuclear autoantigens [1].
Our group demonstrated previously that the extreme N-terminal
(residues 1–85) and C-terminal domains of DFS70/LEDGFp75 (residues
485–530) are removed by caspases during apoptosis, generating
truncated proteins with altered function that still contain an intact
autoepitope/IBD region [54]. These cleaved forms of DFS70/LEDGFp75
could have altered immunogenicity if extracellularly released under a
pro-inﬂammatory environment [9]. Recently, we highlighted that
DFS70/LEDGFp75 cleavage during apoptosis does not appear to abolish
its localization to apoptotic blebs, suggesting that its cleaved formsmay
be released to the extracellular environment in these particles [9]. We
cannot rule out, however, that DFS70/LEDGFp75 might also be released
from both apoptotic and non-apoptotic cells in other types of cell-
derived particles such as small membrane-based microparticles (MP)
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of intracellular antigens that could have altered immunogenicity
and participate in antigen-autoantibody complexes [55,56]. Although
there is no evidence at the present time for the presence of DFS70/
LEDGFp75 in cell-derived microvesicles, there is some circumstantial
evidence for its extracellular release as part of the cellular response to
stress, and that its interaction with its cognate autoantibodies in the
extracellular microenvironment could have pathogenic consequences
[reviewed in 9].
The characterization of the antigenic speciﬁcity of the DFS-IIF pat-
tern is essential for developing highly accurate assays to detect the pres-
ence of anti-DFS70/LEDGFp75 autoantibodies and to evaluate their
clinical signiﬁcance. Although recent advances on the functional analy-
sis of DFS70/LEDGFp75 have shed some light into itsmultiplemolecular
and cellular roles, the clinical and biological signiﬁcance of its cognate
autoantibodies still remains an enigma [9,41,57]. Whereas most cell-
derived autoantigens are targeted preferentially by autoantibodies
associated with speciﬁc organ-speciﬁc or systemic autoimmune
diseases [1,58–60], and even in certain cancer types [61], to date
DFS70/LEDGFp75 remains as an autoantigen without a speciﬁc
clinical association [9].
What then are theDFS70/LEDGFp75 autoantibodies trying to tell us?
While we do not have yet the answer to this question, it is likely that
these autoantibodies may not be the result of pathogenic events associ-
ated with a particular clinical condition. It is conceivable, however,
based on our current knowledge of this autoantigen-autoantibody sys-
tem, that these antibodies could be biosensors of molecular events,
not necessarily speciﬁc to a particular disease, that involve altered
DFS70/LEDGFp75 expression in a microenvironment characterized by
inﬂammation and tissue damage [9]. This would be consistent with
the observed cellular and tissue overexpression of DFS70/LEDGFp75 in
response to environmental stressors such as oxidative stress, irradia-
tion, starvation, chemotherapeutic drugs, and certain viruses such as
the humanpapillomavirus (HPV) [15–18,22,33]. Combinedwith its pro-
teolytic cleavage or other structural modiﬁcations, DFS70/LEDGFp75
overexpression under a stressful, pro-inﬂammatory microenvironment
could break immune tolerance, resulting in a speciﬁc autoantibody re-
sponse to this protein that bypasses its interacting partners. Depending
on the clinical context in which they arise, these autoantibodies could
then play protective or pathogenic roles, or just simply be an epiphe-
nomenon unrelated to the spectrum of clinical conditions in which
they are detected, and coincident with yet to be deﬁned environmental,
immunological, or genetic factors [9].
Finally, although our data strongly support single antigenic speciﬁc-
ity for the anti-DFS response, we cannot categorically conclude that the
DFS-IIF pattern is exclusively restricted to autoantibodies to DFS70/
LEDGFp75. Occasionally, we have encountered sera presenting what
looks like the classical DFS-IIF pattern in HEp-2-ANA test slides but
without recognition of a 70–75 kD band in immunoblots or positive re-
activity by DFS70-CIA [unpublished observations]. Immunoblotting
analyses of these sera have failed to reveal any prominent protein
bands in the 15 to 200 kD range (unpublished observations). Careful
analysis of such sera will help determine if they contain autoantibodies
that target a conformational epitope of DFS70/LEDGFp75 that is lost in
the detection assays, or other yet to be identiﬁed proteins associated
with nuclear complexes in which this autoantigen is naturally found.
Given that the clinical associations of anti-DFS70/LEDGFp75 auto-
antibodies are multiple and involve autoimmune, inﬂammatory, and
malignant conditions [9], it would be also important to distinguish
them, usingdifferent approaches, fromother autoantibodies that specif-
ically target antigens of 75 kD such as those targeting autoimmune
enteropathy-related 75 kD antigen (AIE-75) in the immune dysregula-
tion, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX)
[58]. We anticipate that as our basic understanding of the anti-DFS70/
LEDGFp75 autoantibody response increases, its clinico-biological sig-
niﬁcance will unravel, leading to translational applications.Contributors
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